STABLE FORMULATION OF INTEGRIN ANTIBODY
The present invention discloses a stable pharmaceutical formulation of an α4β7antibody, wherein the formulation contains buffer, PEG, salt, amino acid and surfactant and wherein the formulation is devoid of sugar and/or sugar alcohols. The disclosed antibody formulations are liquid formulations, and...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GHOSH, Shrija PAKHALE, Swapnil Vasudeo JAYARAMAN, Murali OJHA, Bimlesh |
| description | The present invention discloses a stable pharmaceutical formulation of an α4β7antibody, wherein the formulation contains buffer, PEG, salt, amino acid and surfactant and wherein the formulation is devoid of sugar and/or sugar alcohols. The disclosed antibody formulations are liquid formulations, and are also suitable to be formulated as a lyophilized powder.
La présente invention concerne une formulation pharmaceutique stable d'un anticorps α4β7, la formulation contenant un tampon, un PEG, un sel, un acide aminé et un tensioactif, la formulation étant exempte de sucre et/ou d'alcools de sucre. Les formulations d'anticorps de l'invention sont des formulations liquides, et sont également appropriées pour être formulées sous la forme d'une poudre lyophilisée. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021070203A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021070203A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021070203A13</originalsourceid><addsrcrecordid>eNrjZFAPDnF08nFVcPMP8g31cQzx9PdT8HdT8PQLcXUP8vRTcPQL8XTyd4nkYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBkaGBuYGRgbGjobGxKkCAH0SJLo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>STABLE FORMULATION OF INTEGRIN ANTIBODY</title><source>esp@cenet</source><creator>GHOSH, Shrija ; PAKHALE, Swapnil Vasudeo ; JAYARAMAN, Murali ; OJHA, Bimlesh</creator><creatorcontrib>GHOSH, Shrija ; PAKHALE, Swapnil Vasudeo ; JAYARAMAN, Murali ; OJHA, Bimlesh</creatorcontrib><description>The present invention discloses a stable pharmaceutical formulation of an α4β7antibody, wherein the formulation contains buffer, PEG, salt, amino acid and surfactant and wherein the formulation is devoid of sugar and/or sugar alcohols. The disclosed antibody formulations are liquid formulations, and are also suitable to be formulated as a lyophilized powder.
La présente invention concerne une formulation pharmaceutique stable d'un anticorps α4β7, la formulation contenant un tampon, un PEG, un sel, un acide aminé et un tensioactif, la formulation étant exempte de sucre et/ou d'alcools de sucre. Les formulations d'anticorps de l'invention sont des formulations liquides, et sont également appropriées pour être formulées sous la forme d'une poudre lyophilisée.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210415&DB=EPODOC&CC=WO&NR=2021070203A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76517</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210415&DB=EPODOC&CC=WO&NR=2021070203A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GHOSH, Shrija</creatorcontrib><creatorcontrib>PAKHALE, Swapnil Vasudeo</creatorcontrib><creatorcontrib>JAYARAMAN, Murali</creatorcontrib><creatorcontrib>OJHA, Bimlesh</creatorcontrib><title>STABLE FORMULATION OF INTEGRIN ANTIBODY</title><description>The present invention discloses a stable pharmaceutical formulation of an α4β7antibody, wherein the formulation contains buffer, PEG, salt, amino acid and surfactant and wherein the formulation is devoid of sugar and/or sugar alcohols. The disclosed antibody formulations are liquid formulations, and are also suitable to be formulated as a lyophilized powder.
La présente invention concerne une formulation pharmaceutique stable d'un anticorps α4β7, la formulation contenant un tampon, un PEG, un sel, un acide aminé et un tensioactif, la formulation étant exempte de sucre et/ou d'alcools de sucre. Les formulations d'anticorps de l'invention sont des formulations liquides, et sont également appropriées pour être formulées sous la forme d'une poudre lyophilisée.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFAPDnF08nFVcPMP8g31cQzx9PdT8HdT8PQLcXUP8vRTcPQL8XTyd4nkYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBkaGBuYGRgbGjobGxKkCAH0SJLo</recordid><startdate>20210415</startdate><enddate>20210415</enddate><creator>GHOSH, Shrija</creator><creator>PAKHALE, Swapnil Vasudeo</creator><creator>JAYARAMAN, Murali</creator><creator>OJHA, Bimlesh</creator><scope>EVB</scope></search><sort><creationdate>20210415</creationdate><title>STABLE FORMULATION OF INTEGRIN ANTIBODY</title><author>GHOSH, Shrija ; PAKHALE, Swapnil Vasudeo ; JAYARAMAN, Murali ; OJHA, Bimlesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021070203A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>GHOSH, Shrija</creatorcontrib><creatorcontrib>PAKHALE, Swapnil Vasudeo</creatorcontrib><creatorcontrib>JAYARAMAN, Murali</creatorcontrib><creatorcontrib>OJHA, Bimlesh</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GHOSH, Shrija</au><au>PAKHALE, Swapnil Vasudeo</au><au>JAYARAMAN, Murali</au><au>OJHA, Bimlesh</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>STABLE FORMULATION OF INTEGRIN ANTIBODY</title><date>2021-04-15</date><risdate>2021</risdate><abstract>The present invention discloses a stable pharmaceutical formulation of an α4β7antibody, wherein the formulation contains buffer, PEG, salt, amino acid and surfactant and wherein the formulation is devoid of sugar and/or sugar alcohols. The disclosed antibody formulations are liquid formulations, and are also suitable to be formulated as a lyophilized powder.
La présente invention concerne une formulation pharmaceutique stable d'un anticorps α4β7, la formulation contenant un tampon, un PEG, un sel, un acide aminé et un tensioactif, la formulation étant exempte de sucre et/ou d'alcools de sucre. Les formulations d'anticorps de l'invention sont des formulations liquides, et sont également appropriées pour être formulées sous la forme d'une poudre lyophilisée.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2021070203A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | STABLE FORMULATION OF INTEGRIN ANTIBODY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T07%3A52%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GHOSH,%20Shrija&rft.date=2021-04-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021070203A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |